2. Academic Validation
  3. Design, Synthesis, and Biological Evaluation of a Novel NIK Inhibitor with Anti-Inflammatory and Hepatoprotective Effects for Sepsis Treatment

Design, Synthesis, and Biological Evaluation of a Novel NIK Inhibitor with Anti-Inflammatory and Hepatoprotective Effects for Sepsis Treatment

  • J Med Chem. 2024 Apr 11;67(7):5617-5641. doi: 10.1021/acs.jmedchem.3c02266.
Nanxia Zhang 1,  Shige Shen 2,  Mengyu Yang 1,  Sijie He 1,  Chunxiao Liu 2,  Hongmei Li 1,  Tao Lu 1 3,  Haichun Liu 4,  Qinghua Hu 2,  Weifang Tang 1,  Yadong Chen 1 3
Affiliations

Affiliations

  • 1 School of Sciences, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • 2 School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • 3 State Key Laboratory of Natural Medicines, School of Science, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • 4 Laboratory of Molecular Design and Drug Discovery, School of Sciences, China Pharmaceutical University, Nanjing 211198, P. R. China.
PMID: 38563549 DOI: 10.1021/acs.jmedchem.3c02266
Abstract

NIK plays a crucial role in the noncanonical NF-κB signaling pathway associated with diverse inflammatory and autoimmune diseases. Our study presents compound 54, a novel NIK inhibitor, designed through a structure-based scaffold-hopping approach from the previously identified B022. Compound 54 demonstrates remarkable selectivity and potency against NIK both in vitro and in vivo, effectively suppressing pro-inflammatory cytokines and nitric oxide production. In mouse models, compound 54 protected against LPS-induced systemic sepsis, reducing AST, ALT, and AKP liver injury markers. Additionally, it also attenuates sepsis-induced lung and kidney damage. Mechanistically, compound 54 blocks the noncanonical NF-κB signaling pathway by targeting NIK, preventing p100 to p52 processing. This work reveals a novel class of NIK inhibitors with significant potential for sepsis therapy.

Figures
Products